Skip to content
Business
Prognosis

Gilead Breast-Cancer Drug Delays Progression by 1.5 Months

  • Company will discuss expanded use of Trodelvy with regulators
  • Survival benefit in study not statistically significant so far
The Gilead Sciences Inc. headquarters in Foster City, California.

The Gilead Sciences Inc. headquarters in Foster City, California.

Photographer: David Paul Morris/Bloomberg

Gilead Sciences Inc.’s Trodelvy delayed progression of a common type of advanced breast cancer by 1.5 months in a study, a modest but statistically significant improvement that may help expand use of the medicine.

The drug is already approved for an uncommon type of breast cancer called triple negative, but Gilead is now targeting the much larger group of hormone-positive breast cancer patients who have failed other therapies. The data are being presented at the American Society of Clinical Oncology meeting on Saturday.